Axitinib vs Fruquintinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Renal Cell Carcinoma
Shared mechanism: VEGFR1/2/3 · full Renal Cell Carcinoma pipeline
Axitinib
Marketed by Pfizer
NCT02853331 · Phase 3 · completed
This was a large randomized active-controlled trial (432 participants received pembrolizumab plus axitinib and 429 received sunitinib), with blinded independent imaging review but no treatment masking. Both primary endpoints were met favorably: progression-free survival improved (hazard ratio 0.69, p=0.00012) and overall survival improved (hazard ratio 0.53, p=0.00005), but the open-label design limits the evidence grade.
Next expected readout: December 2026 · NCT05768464 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants (From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)); Overall Survival (OS) in PD-L1 Positive Participants (From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)): Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results). (mixed)
Result source: NCT02684006
Fruquintinib · Fruzaqla / Elunate
Marketed by Takeda Pharmaceutical Company and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT05831891 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Renal Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Fruquintinib: no structured comparison results are available for Renal Cell Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Axitinib's landscape · Fruquintinib's landscape